AU2002234591A1 - Inhibitors of the e2f-1/cyclin interaction for cancer therapy - Google Patents

Inhibitors of the e2f-1/cyclin interaction for cancer therapy

Info

Publication number
AU2002234591A1
AU2002234591A1 AU2002234591A AU3459102A AU2002234591A1 AU 2002234591 A1 AU2002234591 A1 AU 2002234591A1 AU 2002234591 A AU2002234591 A AU 2002234591A AU 3459102 A AU3459102 A AU 3459102A AU 2002234591 A1 AU2002234591 A1 AU 2002234591A1
Authority
AU
Australia
Prior art keywords
inhibitors
cancer therapy
cyclin
interaction
cyclin interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002234591A
Inventor
Kenneth Walter Bair
Ying-Nan Pan Chen
Timothy Michael Ramsey
Michael Lloyd Sabio
Sushil Kumar Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002234591A1 publication Critical patent/AU2002234591A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2002234591A 2000-12-20 2001-12-19 Inhibitors of the e2f-1/cyclin interaction for cancer therapy Abandoned AU2002234591A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25682800P 2000-12-20 2000-12-20
US60/256,828 2000-12-20
PCT/EP2001/015006 WO2002050102A2 (en) 2000-12-20 2001-12-19 Inhibitors of the e2f-1/cyclin interaction for cancer therapy

Publications (1)

Publication Number Publication Date
AU2002234591A1 true AU2002234591A1 (en) 2002-07-01

Family

ID=22973745

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002234591A Abandoned AU2002234591A1 (en) 2000-12-20 2001-12-19 Inhibitors of the e2f-1/cyclin interaction for cancer therapy

Country Status (8)

Country Link
US (1) US20020142966A1 (en)
EP (1) EP1345957A2 (en)
JP (1) JP2004516301A (en)
CN (1) CN1592752A (en)
AU (1) AU2002234591A1 (en)
BR (1) BR0116330A (en)
CA (1) CA2432031A1 (en)
WO (1) WO2002050102A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449544B2 (en) * 1999-11-30 2008-11-11 Cyclacel Limited p21 peptides
EP1478405A2 (en) * 2002-01-28 2004-11-24 Novartis AG Beta-homolysine conjugates and their use as transport enhancer
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
EA201100464A1 (en) 2011-04-06 2012-10-30 Ооо "Метамакс" (Ооо "Метамах") PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES AND ITS APPLICATION
WO2019023634A1 (en) 2017-07-28 2019-01-31 Circle Pharma, Inc. Cyclative release of peptidic compounds
CN112608367B (en) * 2021-03-08 2021-06-11 暨南大学 Non-natural amino acid short peptide and application thereof in anti-tumor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7676894A (en) * 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
US5625031A (en) * 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
GB9928323D0 (en) * 1999-11-30 2000-01-26 Cyclacel Ltd Peptides

Also Published As

Publication number Publication date
JP2004516301A (en) 2004-06-03
EP1345957A2 (en) 2003-09-24
BR0116330A (en) 2004-02-25
CN1592752A (en) 2005-03-09
WO2002050102A2 (en) 2002-06-27
CA2432031A1 (en) 2002-06-27
US20020142966A1 (en) 2002-10-03
WO2002050102A3 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001282717A1 (en) Cancer treatment by combination therapy
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
EP1176964B8 (en) Uses of et743 for treating cancer
AUPQ923100A0 (en) Treatment of prostate cancer
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
AU2001268467A1 (en) Identification of genes and compounds for treatment of cancer
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2001290165A1 (en) Components of canola for the treatment of cancer
AU2002217866A1 (en) Geldanamycin derivatives useful for the treatment of cancer
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU6062900A (en) Substituted indole compounds and their use for the treatment of cancer
AU2002351374A1 (en) Antibodies to treat cancer
AU1916601A (en) Oncolytic combinations for the treatment of cancer
AU2001232060A1 (en) Use of cyp1b1 inhibitors for treating cancer
AU2001253836A1 (en) Method of treating cancer
AU7363000A (en) Method for reducing the risk of cancer
AU2002234591A1 (en) Inhibitors of the e2f-1/cyclin interaction for cancer therapy
AU1916501A (en) Oncolytic combinations for the treatment of cancer
AU2001214116A1 (en) Novel paclitaxel derivatives for the treatment of cancer
AU7636800A (en) Improved ricin-like toxins for treatment of cancer
AU1595001A (en) Oncolytic combinations for the treatment of cancer
AU1917101A (en) Oncolytic combinations for the treatment of cancer